Novartis AG Revenue & Financials

Novartis AG reported $54.5 billion in net sales for FY2025, representing an 8% increase at constant currency compared to FY2024, driven by the rapid scaling of its oncology and immunology franchises which successfully offset the decline of legacy cardiovascular assets. The company's operating income surged to $17.644 billion, reflecting a highly efficient cost structure that delivered a 42.2% core operating income margin, one of the highest in the global pharmaceutical industry. Net income reached $13.967 billion, while free cash flow generation remained exceptionally strong at $17.596 billion, providing the financial flexibility to fund a $10.8 billion R&D budget and execute strategic acquisitions. The FY2025 financial results highlight a company in the midst of a successful portfolio transition. While Entresto sales declined significantly in the second half of the year due to US generic entry, the combined sales of Kisqali ($4.7 billion), Cosentyx ($6.6 billion), Kesimpta ($4.4 billion), and Pluvicto ($2.0 billion) demonstrated that the next generation of blockbusters is achieving commercial scale faster than anticipated. The company's gross margin remained stable at approximately 78%, reflecting the pricing power of its patented portfolio despite increasing manufacturing costs for complex modalities like radioligands and gene therapies. Selling, general, and administrative expenses were tightly controlled, growing at a slower rate than revenue, which contributed to the margin expansion. The balance sheet remains fortress-like, with substantial cash reserves and manageable debt levels, allowing Novartis to maintain a progressive dividend policy while executing a $10 billion share buyback program authorized in 2025. This capital return strategy is designed to support the stock price during the transition period between legacy patent cliffs and new product launches, signaling management's confidence in the long-term cash generation capabilities of the pure-play innovative model. The FY2025 financial performance validates the strategic decision to spin off Sandoz, as the removal of the low-margin generics business has significantly improved the company's overall profitability metrics and return on invested capital. The detailed breakdown of the FY2025 income statement reveals the underlying drivers of this financial success. Net sales of $54.5 billion were composed of $24.5 billion from the US market, $16.2 billion from Europe, $8.1 billion from international markets including Japan and China, and $5.7 billion from the rest of the world. The US market remains the most profitable region, contributing approximately 45% of total revenue but an even higher percentage of operating profit due to the significantly higher pricing power for innovative medicines in the United States compared to Europe and Asia. The cost of goods sold (COGS) was $12.0 billion, resulting in a gross profit of $42.5 billion and a gross margin of 78.0%. This high gross margin is characteristic of the innovative pharmaceutical industry and reflects the relatively low marginal cost of manufacturing small molecule drugs and biologics once the initial capital-intensive manufacturing facilities have been built and the regulatory approvals have been obtained. Research and development expenses totaled $10.8 billion, representing 19.8% of net sales. This substantial R&D investment is critical for maintaining the company's competitive position and driving future growth, and it is allocated across a diverse portfolio of early-stage discovery programs, Phase I and II clinical trials, and large-scale Phase III registrational studies. Selling, general, and administrative (SG&A) expenses were $14.1 billion, or 25.9% of net sales, reflecting the significant commercial investment required to launch and support the company's growing portfolio of innovative medicines. The core operating income of $17.644 billion was achieved after deducting amortization of intangible assets of $1.2 billion and other operating income/expenses of $0.4 billion, resulting in a core operating margin of 42.2%. This exceptional margin performance is a testament to the company's rigorous cost management practices and the high operating leverage inherent in the innovative pharmaceutical business model. The net income of $13.967 billion was achieved after deducting income taxes of $3.677 billion, resulting in an effective tax rate of 20.8%, which is slightly below the statutory rate due to the favorable geographic mix of the company's profits and the utilization of various tax credits and incentives. The strong cash flow generation of $17.596 billion provided the company with the financial flexibility to return $10.2 billion to shareholders through dividends and share buybacks, while also funding $6.4 billion in strategic acquisitions and capital expenditures. The balance sheet at the end of FY2025 showed total assets of $105.3 billion, total liabilities of $62.1 billion, and total equity of $43.2 billion, resulting in a debt-to-equity ratio of 0.85, which is well within the company's target range and provides a strong foundation for future growth and capital allocation initiatives.